首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2349251篇
  免费   172146篇
  国内免费   3319篇
耳鼻咽喉   32049篇
儿科学   75896篇
妇产科学   62685篇
基础医学   348170篇
口腔科学   63620篇
临床医学   211341篇
内科学   457275篇
皮肤病学   51727篇
神经病学   185264篇
特种医学   88007篇
外国民族医学   489篇
外科学   353859篇
综合类   47508篇
现状与发展   12篇
一般理论   848篇
预防医学   182735篇
眼科学   54337篇
药学   175096篇
  11篇
中国医学   4575篇
肿瘤学   129212篇
  2021年   18978篇
  2019年   19537篇
  2018年   27057篇
  2017年   20357篇
  2016年   22745篇
  2015年   25638篇
  2014年   36094篇
  2013年   53952篇
  2012年   74674篇
  2011年   79405篇
  2010年   47055篇
  2009年   44564篇
  2008年   74607篇
  2007年   79475篇
  2006年   80293篇
  2005年   77777篇
  2004年   74365篇
  2003年   71689篇
  2002年   69362篇
  2001年   108738篇
  2000年   111451篇
  1999年   93494篇
  1998年   26990篇
  1997年   23658篇
  1996年   24054篇
  1995年   22715篇
  1994年   20893篇
  1993年   19712篇
  1992年   72000篇
  1991年   70069篇
  1990年   68391篇
  1989年   65663篇
  1988年   60302篇
  1987年   59126篇
  1986年   55217篇
  1985年   53004篇
  1984年   39311篇
  1983年   33396篇
  1982年   19860篇
  1979年   35866篇
  1978年   25651篇
  1977年   21230篇
  1976年   20332篇
  1975年   21816篇
  1974年   26148篇
  1973年   24803篇
  1972年   23200篇
  1971年   22037篇
  1970年   20247篇
  1969年   19315篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
181.
182.
183.
184.
185.
186.
The special interest group on sensitive skin of the International Forum for the Study of Itch previously defined sensitive skin as a syndrome defined by the occurrence of unpleasant sensations (stinging, burning, pain, pruritus and tingling sensations) in response to stimuli that normally should not provoke such sensations. This additional paper focuses on the pathophysiology and the management of sensitive skin. Sensitive skin is not an immunological disorder but is related to alterations of the skin nervous system. Skin barrier abnormalities are frequently associated, but there is no cause and direct relationship. Further studies are needed to better understand the pathophysiology of sensitive skin – as well as the inducing factors. Avoidance of possible triggering factors and the use of well-tolerated cosmetics, especially those containing inhibitors of unpleasant sensations, might be suggested for patients with sensitive skin. The role of psychosocial factors, such as stress or negative expectations, might be relevant for subgroups of patients. To date, there is no clinical trial supporting the use of topical or systemic drugs in sensitive skin. The published data are not sufficient to reach a consensus on sensitive skin management. In general, patients with sensitive skin require a personalized approach, taking into account various biomedical, neural and psychosocial factors affecting sensitive skin.  相似文献   
187.
188.
Treatment decisions in patients with metastatic bone disease rely on accurate survival estimation. We developed the original PATHFx models using expensive, proprietary software and now seek to provide a more cost-effective solution. Using open-source machine learning software to create PATHFx version 2.0, we asked whether PATHFx 2.0 could be created using open-source methods and externally validated in two unique patient populations. The training set of a well-characterized, database records of 189 patients and the bnlearn package within R Version 3.5.1 (R Foundation for Statistical Computing), was used to establish a series of Bayesian belief network models designed to predict survival at 1, 3, 6, 12, 18, and 24 months. Each was externally validated in both a Scandinavian (n = 815 patients) and a Japanese (n = 261 patients) data set. Brier scores and receiver operating characteristic curves to assessed discriminatory ability. Decision curve analysis (DCA) evaluated whether models should be used clinically. DCA showed that the model should be used clinically at all time points in the Scandinavian data set. For the 1-month time point, DCA of the Japanese data set suggested to expect better outcomes assuming all patients will survive greater than 1 month. Brier scores for each curve demonstrate that the models are accurate at each time point. Statement of Clinical Significance: we successfully transitioned to PATHFx 2.0 using open-source software and externally validated it in two unique patient populations, which can be used as a cost-effective option to guide surgical decisions in patients with metastatic bone disease.  相似文献   
189.
In May 2017, the Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee hosted a workshop to discuss whether mode of action (MOA) investigation is enhanced through the application of the adverse outcome pathway (AOP) framework. As AOPs are a relatively new approach in genetic toxicology, this report describes how AOPs could be harnessed to advance MOA analysis of genotoxicity pathways using five example case studies. Each of these genetic toxicology AOPs proposed for further development includes the relevant molecular initiating events, key events, and adverse outcomes (AOs), identification and/or further development of the appropriate assays to link an agent to these events, and discussion regarding the biological plausibility of the proposed AOP. A key difference between these proposed genetic toxicology AOPs versus traditional AOPs is that the AO is a genetic toxicology endpoint of potential significance in risk characterization, in contrast to an adverse state of an organism or a population. The first two detailed case studies describe provisional AOPs for aurora kinase inhibition and tubulin binding, leading to the common AO of aneuploidy. The remaining three case studies highlight provisional AOPs that lead to chromosome breakage or mutation via indirect DNA interaction (inhibition of topoisomerase II, production of cellular reactive oxygen species, and inhibition of DNA synthesis). These case studies serve as starting points for genotoxicity AOPs that could ultimately be published and utilized by the broader toxicology community and illustrate the practical considerations and evidence required to formalize such AOPs so that they may be applied to genetic toxicity evaluation schemes. Environ. Mol. Mutagen. 61:114–134, 2020. © 2019 Wiley Periodicals, Inc.  相似文献   
190.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号